Keyphrases
Overexpression
100%
Clinical Characteristics
100%
Multiple Myeloma
100%
Prognostic Value
100%
Possible Mechanisms
100%
Enhancer of Zeste Homolog 2 (EZH2)
100%
Characteristic Mechanisms
100%
Confidence Interval
25%
CoMMpass
25%
Median Overall Survival
16%
Malignancy
16%
Overall Survival
8%
Worse Outcome
8%
Clinical Data
8%
Genomic Data
8%
KRAS mutation
8%
Poor Prognosis
8%
Poor Outcome
8%
Histone Methyltransferase
8%
Interim Analysis
8%
Clinical Expression
8%
Missense mutation
8%
Clinical Genomics
8%
Tumor Protein p53 (TP53)
8%
Genetic mutation
8%
Progression-free
8%
Cell Cycle Control
8%
Expression Data
8%
Lab-based
8%
Medicine and Dentistry
Multiple Myeloma
100%
Overall Survival
60%
Cancer
40%
Progression Free Survival
20%
Clinical Study
20%
Gene Mutation
20%
Protein P53
20%
Histone Methyltransferase
20%
Missense Mutation
20%
Interim Analysis
20%
Cell Cycle Regulation
20%
Immunology and Microbiology
Multiple Myeloma
100%
Overall Survival
60%
P53
20%
Gene Mutation
20%
Cell Cycle Regulation
20%
Progression Free Survival
20%
Missense Mutation
20%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Overall Survival
60%
Progression Free Survival
20%
Clinical Study
20%
Histone Methyltransferase
20%
Protein P53
20%
Biochemistry, Genetics and Molecular Biology
EZH2
100%
Overall Survival
25%
Gene Mutation
8%
P53
8%
Clinical Study
8%
Histone Methyltransferase
8%
KRAS
8%
Missense Mutation
8%
Cell Cycle Regulation
8%
Progression Free Survival
8%
Genomics
8%